Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELAZA: Azacitidine for hematologic relapse after allogeneic HSCT in AML/MDS
2006-001040-31Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Jul 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Technische Universität Dresden. Primary endpoints: Efficacy of azacitidine in post-transplant hematologic relapse and Safety of azacitidine in post-transplant hematologic relapse. Started Jul 2006; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2006-001040-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001040-31.